Investigation of the female infertility risk associated with anti-cancer therapy

被引:0
|
作者
Atiye Lavafian
Parmida Sadat Pezeshki
Nima Rezaei
机构
[1] Iran University of Medical Sciences,School of Medicine
[2] Universal Scientific Education and Research Network (USERN),Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA)
[3] Tehran University of Medical Sciences,School of Medicine
[4] Universal Scientific Education and Research Network (USERN),Cancer Immunology Project (CIP)
[5] Tehran University of Medical Sciences,Research Center for Immunodeficiencies, Children’s Medical Center
[6] Tehran University of Medical Sciences,Department of Immunology, School of Medicine
来源
关键词
Female infertility; Anti-cancer therapy; Breast cancer; Gynecological cancer; Ovarian cancer; Uterine cancer, Cervical cancer;
D O I
暂无
中图分类号
学科分类号
摘要
Female infertility is a significant health issue worldwide with a rising incidence. Anti-cancer therapy is one of the most important reasons for increasing infertility. Although anti-cancer treatment increases the rate of survival, it decreases the quality of life through its side effects. The most substantial side effects are sexual dysfunction and infertility. Breast cancer is the most common cancer. The first-line treatment of breast cancer is chemotherapy by alkylating agents like cyclophosphamide, which leads to infertility. For instance, persistent chemotherapy-induced amenorrhea among breast cancer patients could affect almost half of the patients that undergo such therapy. However, some agents or therapeutic methods can ameliorate these intoxicating effects. Chemotherapy plus gonadotropin-releasing hormone agonist, in breast cancer patients, can not only improve overall survival but also reduce ovarian toxicity. Age plays an essential role in chemotherapy-induced amenorrhea. Chemotherapy at a younger age can reduce the risk of infertility. Gynecological cancers including uterine and ovarian cancer, which have high mortality rates, are the most related cancers to infertility. Surgery is the primary treatment of gynecological cancers. Studies demonstrated that fertility-sparing surgery is a better option than radical surgery. In addition, neoadjuvant chemotherapy is mostly a better option than primary cytoreductive surgery in terms of survival and fertility. Immune checkpoint inhibitors (ICIs) have recently played a major role in treating various cancer types. However, ICIs are associated with hypophysitis, which affects ovaries and can lead to infertility. There are some options for ovarian preservation such as embryo cryopreservation, oocyte cryopreservation, ovarian transposition, ovarian tissue cryopreservation, and ovarian suppression by GnRH agonists. Anti-müllerian hormone level can be utilized to monitor the ovarian reserve. Moreover, to avoid fertility loss, approaches such as using transplantation of human placenta mesenchymal stem cells, administrating anti-inflammatory agents and hormone therapy are under investigation.
引用
收藏
页码:1893 / 1905
页数:12
相关论文
共 50 条
  • [1] Investigation of the female infertility risk associated with anti-cancer therapy
    Lavafian, Atiye
    Pezeshki, Parmida Sadat
    Rezaei, Nima
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2023, 25 (07): : 1893 - 1905
  • [2] Renal dysfunction is associated with a higher risk of cardiotoxicity following anti-cancer therapy among female patients with early breast cancer
    Ciou, Wan-Jyun
    Ho, Chin-Chin
    Yang, Chen-Chang
    CLINICAL TOXICOLOGY, 2018, 56 (06) : 566 - 567
  • [3] Targeting tumor associated macrophages for anti-cancer therapy
    Guerriero, Jennifer L.
    CANCER IMMUNOLOGY RESEARCH, 2022, 10 (01)
  • [4] Potential ovarian toxicity and infertility risk following targeted anti-cancer therapies
    Rosario, Roseanne
    Cui, Wanyuan
    Anderson, Richard A.
    REPRODUCTION AND FERTILITY, 2022, 3 (03): : R147 - R162
  • [5] Use of natural products in anti-cancer alternative therapy: risk of interactions with conventional anti-cancer drugs
    Rodeiro, Idania
    Magarino, Yack
    Ocejo, Omar
    Garrido, Gabino
    Delgado, Rene
    BOLETIN LATINOAMERICANO Y DEL CARIBE DE PLANTAS MEDICINALES Y AROMATICAS, 2008, 7 (06): : 332 - 344
  • [6] The microbiome in anti-cancer therapy
    Bashiardes, Stavros
    Tuganbaev, Timur
    Federici, Sara
    Elinav, Eran
    SEMINARS IN IMMUNOLOGY, 2017, 32 (0C) : 74 - 81
  • [7] microRNAs as Anti-Cancer Therapy
    Garofalo, Michela
    Di Leva, Gianpiero
    Croce, Carlo M.
    CURRENT PHARMACEUTICAL DESIGN, 2014, 20 (33) : 5328 - 5335
  • [8] Anti-cancer therapy success
    Wong, JF
    GENETIC ENGINEERING NEWS, 2005, 25 (11): : 48 - 49
  • [9] PHARMACOGENETICS OF ANTI-CANCER THERAPY
    van Schaik, Ron H. N.
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2011, 49 : S49 - S49
  • [10] Viral anti-cancer therapy
    Blazejewska, Paulina
    Gozdzicka-Jozefiak, Anna
    WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2005, 9 (07): : 279 - 283